Fintel reports that on December 8, 2025, Oppenheimer maintained coverage of Capricor Therapeutics (NasdaqCM:CAPR) with a ...

B. Riley raised the firm’s price target on Capricor Therapeutics (CAPR) to $50 from $21 and keeps a Buy rating on the shares. The clinical data ...

Capricor Therapeutics, Inc. soars 450% on positive HOPE-3 DMD results. Discover market impact, growth potential, and risks.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key ...

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...

As of Monday, November 24, Capricor Therapeutics, Inc.’s CAPR share price has dipped by 9.03%, which has investors ...

Capricor jumps after Phase 3 data show Deramiocel improves heart function and slows muscle decline in Duchenne muscular ...

In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...